SENS 01
Alternative Names: SENS-01Latest Information Update: 02 Feb 2024
At a glance
- Originator Sensorium Therapeutics
- Class Antidepressants; Anxiolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Depressive disorders
Most Recent Events
- 30 Jan 2024 Sensorium Therapeutics plans to initiate clinical trials for Anxiety disorders and Depressive disorders in 2025
- 23 Oct 2023 Preclinical trials in Anxiety disorders in USA (unspecified route) before October 2023 (Sensorium Therapeutics pipeline, October 2023)
- 23 Oct 2023 Preclinical trials in Depressive disorders in USA (unspecified route) before October 2023 (Sensorium Therapeutics pipeline, October 2023)